20 documents found, page 1 of 2
Motor symptoms and the quality of life of relapsing-remitting multiple sclerosi...
Jorge,Francielle Fontana; Finkelsztejn,Alessandro; Rodrigues,Luciano PalmeiroAbstract Background: Spasticity, fatigue, muscle weakness and changes in gait are some of the main motor symptoms of Multiple Sclerosis (MS). These changes can interfere with the patients’ quality of life. Objective: To characterize the motor and quality of life symptoms in patients with relapsing-remitting Multiple Sclerosis at a specialized center. Methods: Fifty five patients at the Neuroimmunology Outpatien...
Normative values of the Brief Repeatable Battery of Neuropsychological Tests in...
Damasceno,Alfredo; Amaral,Juliana Machado Santiago dos Santos; Barreira,Amilton Antunes; Becker,Jefferson; Callegaro,Dagoberto; Campanholo,Kenia RepisoABSTRACT Objective Cognitive dysfunction is common in multiple sclerosis. The Brief Repeatable Battery of Neuropsychological Tests (BRB–N) was developed to assess cognitive functions most–frequently impaired in multiple sclerosis. However, normative values are lacking in Brazil. Therefore, we aimed to provide continuous and discrete normative values for the BRB–N in a Brazilian population sample. Methods We rec...
Basal cortisol levels and the relationship with clinical symptoms in multiple s...
Pereira,Gabriela Magalhães; Soares,Nayron Medeiros; Souza,Andreo Rysdyk de; Becker,Jefferson; Finkelsztejn,Alessandro; Almeida,Rosa Maria Martins deABSTRACT Multiple sclerosis (MS) is a demyelinating, progressive and neurodegenerative disease. A disturbance on the hypothalamic-pituitary-adrenal axis can be observed in patients with MS, showing altered cortisol levels. We aimed to identify basal cortisol levels and verify the relationship with clinical symptoms in patients with MS. A systematic search was conducted in the databases: Pubmed, Web of Science a...
Autosomal recessive spastic ataxia of Charlevoix-Saguenay: a family report from...
Burguêz,Daniela; Oliveira,Camila Maria de; Rockenbach,Marcio Aloísio Bezerra Cavalcanti; Fussiger,Helena; Vedolin,Leonardo Modesti; Winckler,Pablo BreaABSTRACT Autosomal recessive spastic ataxia of Charlevoix-Saguenay (ARSACS) is an early-onset, neurodegenerative disorder caused by mutations in SACS, firstly reported in Quebec, Canada. The disorder is typically characterized by childhood onset ataxia, spasticity, neuropathy and retinal hypermyelination. The clinical picture of patients born outside Quebec, however, is often atypical. In the present article, t...
Patients’ satisfaction with and views about treatment with disease-modifying dr...
Spessotto,Caroline Vieira; Cavalli,Hanaie; Eboni,Audred Cristina Biondo; Machado,Rafael Berlezi; Mousquer,Analara Munardi; Palazzo,Lara BothABSTRACT Objective The treatment of multiple sclerosis (MS) with disease-modifying-drugs (DMDs) is evolving and new drugs are reaching the market. Efficacy and safety aspects of the drugs are crucial, but the patients’ satisfaction with the treatment must be taken into consideration. Methods Individual interview with patients with MS regarding their satisfaction and points of view on the treatment with DMDs. Re...
The prevalence of multiple sclerosis in Santa Maria, Rio Grande do Sul, Brazil
Finkelsztejn,Alessandro; Lopes,Juarez Silva; Noal,Janaína; Finkelsztejn,Juliana M.Multiple sclerosis (MS) is one of the leading causes of neurologic deficits in young adults and can lead to physical, intellectual and emotional problems. Approved treatments are expensive and are among the 10 highest budgets of the Brazilian Health Ministry. Given the diverse prevalence of MS among Brazilian regions, it is important to determine prevalence rates across the country. Seven studies have assessed ...
The real-life experience with cardiovascular complications in the first dose of...
Fragoso,Yara Dadalti; Arruda,Christian Cardoso; Arruda,Walter Oleschko; Brooks,Joseph Bruno Bidin; Damasceno,AlfredoFingolimod is a new and efficient treatment for multiple sclerosis (MS). The drug administration requires special attention to the first dose, since cardiovascular adverse events can be observed during the initial six hours of fingolimod ingestion. The present study consisted of a review of cardiovascular data on 180 patients with MS receiving the first dose of fingolimod. The rate of bradycardia in these patie...
Nearly one-half of Brazilian patients with multiple sclerosis using natalizumab...
Fragoso,Yara Dadalti; Mendes,Maria Fernanda; Arruda,Walter Oleschko; Becker,Jefferson; Brooks,Joseph Bruno Bidin; Carvalho,Margarete de JesusObjective Natalizumab is a new and efficient treatment for multiple sclerosis (MS). The risk of developing progressive multifocal leukoencephalopathy (PML) during the use of this drug has created the need for better comprehension of JC virus (JCV) infection. The objective of the present study was to assess the prevalence of JCV-DNA in Brazilian patients using natalizumab. Method Qualitative detection of the JCV...
Multiple sclerosis starting before the age of 18 years: the Brazilian experience
Fragoso,Yara Dadalti; Ferreira,Maria Lucia Brito; Morales,Nivea de Macedo Oliveira; Arruda,Walter Oleschko; Brooks,Joseph Bruno BidinMultiple sclerosis (MS) starting in childhood and adolescence poses a challenge for diagnosis and management of the disease. The aim of the present study was to assess the characteristics of early onset MS in Brazilian patients. Methods Retrospective data collection from specialized MS units. Results From 20 MS units in 11 Brazilian states, 117 cases of MS starting before the age of 18 years were collected. The...
Latin American algorithm for treatment of relapsing-remitting multiple sclerosi...
Finkelsztejn,Alessandro; Gabbai,Alberto Alain; Fragoso,Yara Dadalti; Carrá,Adriana; Macías-Islas,Miguel Angel; Arcega-Revilla,Raul; García-Bonitto,JuanOBJECTIVE: It is estimated that circa 50,000 individuals have relapsing-remitting multiple sclerosis in Latin America. European and North-American algorithms for the treatment of multiple sclerosis do not foresee our regional difficulties and the access of patients to treatment. METHODS: The Latin American Multiple Sclerosis Forum is an independent and supra-institutional group of experts that has assessed the ...